# UK Neuropsychiatric Disorders Treatment Market > UK Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.5% - **2024:** $ 5.45 Billion - **2025:** $ 6.02 Billion - **2035:** $ 16.35 Billion - **Key Players:** Johnson & Johnson (US), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Roche (CH), Otsuka Pharmaceutical (JP) **Report ID:** MRFR/HC/43511-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-neuropsychiatric-disorders-treatment-market-45191 --- ## Market Summary ## **UK Neuropsychiatric Disorders Treatment Market Overview** As per MRFR analysis, the UK Neuropsychiatric Disorders Treatment Market Size was estimated at 5.92 (USD Billion) in 2023.The UK Neuropsychiatric Disorders Treatment Market Industry is expected to grow from 6.53(USD Billion) in 2024 to 14.98 (USD Billion) by 2035. The UK Neuropsychiatric Disorders Treatment Market CAGR (growth rate) is expected to be around 7.846% during the forecast period (2025 - 2035). **Key UK Neuropsychiatric Disorders Treatment Market Trends Highlighted** In the UK, the Neuropsychiatric Disorders Treatment Market is witnessing significant growth driven by various factors. The increasing prevalence of neuropsychiatric disorders such as depression, anxiety, and schizophrenia are a key market driver. Recent reports indicate that mental health issues are a leading cause of disability in the UK, prompting a greater need for effective treatments and care options. There is a growing awareness and reduction of stigma associated with mental health, which encourages individuals to seek help, thereby increasing demand for treatments. Opportunities exist in the form of advancements in telemedicine and digital health.The regulatory landscape is becoming more adaptive as the National Health Service (NHS) works to incorporate novel treatments into its offerings. With emphasis on mental health in societal discussions, the landscape for neuropsychiatric treatment is evolving, and stakeholders need to adapt to these changes to meet the growing demand effectively. **UK Neuropsychiatric Disorders Treatment Market Drivers** **Rising Prevalence of Neuropsychiatric Disorders** The surge in the UK Neuropsychiatric disorders Treatment Market Industry is driven primarily due to the increase in the rates of neuropsychiatric disorders. The NHS indicates that every year 1 out of 4 people will undergo some form of mental health issue. According to the Mental Health Foundation, nearly 8 million people in the UK are suffering from neuropsychiatric disorders like depression, anxiety, and even bipolar disorder. This increasing figure needs new and better treatment alternatives, thus increasing the market size. Some of the big pharmaceutical companies like GlaxoSmithKline are already developing new therapies for these disorders, which shows the positive direction the market is moving to serve the increasing patients. **Government Initiatives and Funding** Government policies and initiatives aimed at addressing mental health issues are crucial drivers for the UK Neuropsychiatric Disorders Treatment Market Industry. The UK government has pledged significant funding towards mental health services, including the 'Mental Health Investment Standard' which requires Clinical Commissioning Groups to increase their mental health budgets. Recent government reports indicate that these budgets are expected to rise by 10% annually, ensuring a steady flow of resources dedicated to improving treatments for neuropsychiatric disorders.This funding not only supports the development of innovative therapies and medications but also allows the integration of mental health services into primary care, significantly impacting market growth and accessibility. **Increased Awareness and Reduced Stigma** There is a growing awareness of neuropsychiatric disorders in the UK, leading to a decrease in stigma associated with mental health conditions. Public campaigns led by organizations like Mind and the Time to Change initiative have played a vital role in educating the public about mental health. Research indicates that more than 50% of people in the UK now believe that acknowledging mental health issues is important, which has resulted in increased willingness to seek treatment.This heightened awareness is crucial for the UK Neuropsychiatric Disorders Treatment Market Industry as it encourages individuals to seek help, driving demand for various treatments and therapies that address neuropsychiatric conditions. **UK Neuropsychiatric Disorders Treatment Market Segment Insights** **Neuropsychiatric Disorders Treatment Market Type Insights** The UK Neuropsychiatric Disorders Treatment Market is showing robust development, particularly in the Type category, which encompasses several classifications of disorders including Degenerative Diseases, Neurotic Disorders, Psychosis, and Others, each playing a substantial role in the overall healthcare landscape. The increasing prevalence of neurological and psychiatric disorders in the UK is fueling awareness and leading to enhanced demand for effective treatment solutions. Specifically, Degenerative Diseases often reflect chronic conditions such as Alzheimer’s and Parkinson’s, which are becoming more prominent as the aging population grows. This demographic shift highlights the need for targeted treatments to manage symptoms and improve quality of life for affected individuals. Neurotic Disorders, including anxiety and depression, are gaining attention as society increasingly recognizes mental health's impact on everyday functionality, which drives the search for innovative therapies and supportive technologies. Psychosis, encompassing conditions like schizophrenia, poses unique treatment challenges, inspiring significant research and development efforts to advance understanding and management of these complex disorders. In addition to these primary categories, the 'Others' segment includes various less common neuropsychiatric conditions that necessitate tailored treatment options and often gain traction through advocacy and specialized clinical programs. This entire segmentation emphasizes the necessity for a comprehensive approach to neuropsychiatric care in the UK, underpinned by both the urgency to address diverse patient needs and the broader societal commitment to improving mental health outcomes. Furthermore, as healthcare policies evolve to improve access to mental health resources, there lies an expanding opportunity for advancements in treatment methodologies, shaped by current trends in digital health technologies and personalized medicine.The UK Government's initiatives aimed at enhancing mental health services and integrating them into primary care are expected to bolster these efforts substantially, reinforcing the significance of each Type within the Neuropsychiatric Disorders Treatment Market context. **Neuropsychiatric Disorders Treatment Market Application Insights** The UK Neuropsychiatric Disorders Treatment Market focuses on varied applications to address diverse mental health needs. Key applications such as Shock Treatment and Drug Treatment play pivotal roles in providing therapeutic solutions for individuals with neuropsychiatric disorders. Shock Treatment, which includes Electroconvulsive Therapy (ECT), is significant due to its effectiveness in severe depression and other resistant mental illnesses; it often leads to rapid symptom relief where medications fail. Drug Treatment remains a dominant force, offering various pharmacological options tailored to specific conditions, making it essential for long-term management of disorders like schizophrenia and bipolar disorder. Additionally, the others category encompasses emerging therapies and holistic approaches, indicating a growing trend towards personalized treatment plans. This comprehensive understanding of applications in the UK Neuropsychiatric Disorders Treatment Market reveals the evolving landscape influenced by increased awareness, supportive government policies, and ongoing research, which collectively drive market growth and enhance patient outcomes in mental health care. **Neuropsychiatric Disorders Treatment Market End User Insights** The End User segment of the UK Neuropsychiatric Disorders Treatment Market encompasses various critical categories, including hospitals, clinics, research centers, and others, each playing a vital role in addressing neuropsychiatric conditions. Hospitals dominate this space due to their capacity to provide comprehensive treatment options, advanced technologies, and multidisciplinary teams of specialists, which are essential for complex cases. Clinics serve as a vital access point for patients seeking initial diagnosis and ongoing therapy, ensuring continuity of care in outpatient settings.Research centers contribute significantly by driving innovation through clinical trials and studies, which aim to enhance treatment methodologies and understanding of neuropsychiatric disorders. The 'Others' category encompasses specialty facilities and home care services, indicating a trend toward personalized and community-based care solutions. As the UK government continues to prioritize mental health initiatives, the importance of each of these end users will likely increase, driving growth dynamics and evolving service models in the market.Furthermore, with rising public awareness about mental health, all end user categories are positioned to adapt, creating numerous opportunities to enhance patient engagement and treatment outcomes within the UK Neuropsychiatric Disorders Treatment Market. **UK Neuropsychiatric Disorders Treatment Market Key Players and Competitive Insights** The UK Neuropsychiatric Disorders Treatment Market is characterized by a blend of innovation, growing research, and competitive strategy that have shaped its landscape in recent years. The rising prevalence of neuropsychiatric disorders, coupled with increasing awareness among healthcare professionals and patients, has prompted companies to prioritize the development of effective treatments. The market comprises a range of pharmaceutical companies focused on addressing the needs of patients suffering from various conditions, including depression, anxiety, schizophrenia, and bipolar disorder. These companies aim to provide a comprehensive portfolio of solutions that encompass not only pharmacological treatments but also support services, thereby solidifying their market presence amidst fierce competition. Collaborations, mergers, and the pursuit of cutting-edge research are indicators of an evolving market adjusting to both consumer needs and scientific advancements. AstraZeneca holds a significant position in the UK Neuropsychiatric Disorders Treatment Market, leveraging its extensive research and development capabilities to deliver innovative therapeutic solutions. The company’s strengths lie in its robust pipeline of neuropsychiatric medications designed to improve patient outcomes across various conditions. With a dedicated focus on mental health, AstraZeneca has invested in significant collaborative efforts with research institutions and mental health organizations to enhance its understanding of neuropsychiatric disorders and the needs of patients. This strategy not only underlines AstraZeneca's commitment to science-based advancement but also its imperative to maintain a competitive edge in an evolving market characterized by rapid innovations and rising patient demands.Roche, another key player within the UK Neuropsychiatric Disorders Treatment Market, is recognized for its extensive portfolio of medications addressing multiple aspects of neuropsychiatric health. The company offers a range of products specifically targeted at improving mental wellbeing, reflecting its deep commitment to addressing these complex disorders. Roche maintains a solid presence in the UK through its continuous investment in research and development, as well as strategic partnerships aimed at enhancing its drug offerings. The company has made notable strides in merging and acquiring smaller biotech firms, which enriches its capabilities and accelerates its growth trajectory. This strategy not only consolidates Roche's market position but also facilitates the introduction of cutting-edge therapies to the UK population struggling with neuropsychiatric disorders. By focusing on innovation-driven solutions and leveraging its established relationships within the healthcare ecosystem, Roche remains a formidable competitor in this dynamic landscape. **Key Companies in the UK Neuropsychiatric Disorders Treatment Market Include:** - AstraZeneca - Roche - Johnson and Johnson - Sanofi - Otsuka Pharmaceutical - Teva Pharmaceutical - Novartis - AkzoNobel - Pfizer - H Lundbeck - Merck - BristolMyers Squibb - GlaxoSmithKline - AbbVie - Eli Lilly **UK Neuropsychiatric Disorders Treatment Market Industry Developments** The UK Neuropsychiatric Disorders Treatment Market is experiencing significant developments, particularly highlighted by increased investments in mental health therapies. AstraZeneca and Johnson & Johnson are advancing their portfolios, focusing on innovative drugs to tackle neuropsychiatric conditions. In recent months, collaborations involving Roche and Merck have aimed at enhancing the development of therapy, targeting conditions like depression and schizophrenia. Notably, in June 2023, Pfizer announced an expansion in its neuropsychiatry research division, indicating a commitment to addressing urgent treatment gaps in the UK. Mergers and acquisitions have also been notable, with AkzoNobel acquiring a biotech firm in August 2023, strengthening their position in the neuropsychiatric field. Furthermore, the UK government has been investing in mental health initiatives, seeking to allocate 2.3 billion towards mental health support by 2024, reflecting a growing acknowledgment of neuropsychiatric disorders' impact on public health. The market has seen overall growth, with the valuation reaching approximately 1.5 billion in late 2022, significantly influencing treatment accessibility and innovation across the sector. As companies like Novartis and Eli Lilly press on with research funding, the UK market anticipates further advancements in therapeutic solutions. **UK Neuropsychiatric Disorders Treatment Market Segmentation Insights** ## Market Drivers ### Rising Demand for Personalized Medicine The shift towards personalized medicine is emerging as a significant driver in the neuropsychiatric disorders-treatment market. Tailoring treatments to individual patient profiles, including genetic and biomarker considerations, enhances therapeutic efficacy. The UK has seen a growing emphasis on precision psychiatry, with initiatives aimed at developing targeted therapies for specific neuropsychiatric conditions. This approach not only improves treatment outcomes but also reduces the trial-and-error nature of traditional prescribing practices. As healthcare providers increasingly adopt personalized treatment strategies, the neuropsychiatric disorders-treatment market is likely to expand, reflecting the demand for more effective and individualized care. ### Advancements in Pharmacological Treatments Innovations in pharmacological treatments are significantly influencing the neuropsychiatric disorders-treatment market. The development of novel medications, including atypical antipsychotics and rapid-acting antidepressants, has transformed treatment paradigms. For instance, the introduction of ketamine-based therapies has shown promise in treating severe depression, leading to a potential market expansion. Furthermore, the UK government has invested heavily in research and development, with funding exceeding £400 million in recent years. This financial commitment is expected to accelerate the discovery of new therapeutic agents, enhancing treatment efficacy and safety. As a result, the neuropsychiatric disorders-treatment market is poised for growth, driven by these advancements in pharmacotherapy. ### Growing Prevalence of Mental Health Disorders The rising incidence of mental health disorders in the UK is a primary driver for the neuropsychiatric disorders-treatment market. Recent estimates indicate that approximately 1 in 4 individuals in the UK experience mental health issues at some point in their lives. This alarming statistic underscores the urgent need for effective treatment options. The increasing awareness and acceptance of mental health conditions have led to a greater demand for therapeutic interventions. As the stigma surrounding mental health diminishes, more individuals are seeking help, thereby expanding the patient base for treatment providers. Consequently, the neuropsychiatric disorders-treatment market is likely to experience substantial growth as healthcare systems adapt to meet the needs of this expanding population. ### Increased Investment in Mental Health Services The UK government has made substantial investments in mental health services, which serves as a crucial driver for the neuropsychiatric disorders-treatment market. Recent policy initiatives have allocated over £2 billion to improve mental health care accessibility and quality. This funding aims to enhance community-based services, reduce waiting times, and expand treatment options for patients. Additionally, the integration of mental health services into primary care settings is likely to facilitate early intervention and improve patient outcomes. As these investments materialize, the neuropsychiatric disorders-treatment market is expected to benefit from increased service availability and improved patient engagement. ### Technological Integration in Treatment Delivery Technology integration into treatment delivery is reshaping the neuropsychiatric disorders-treatment market. Telemedicine and digital health platforms are becoming increasingly prevalent, allowing for remote consultations and monitoring. This trend is particularly beneficial in the UK, where access to mental health services can be limited in rural areas. The use of mobile applications for therapy and symptom tracking is also gaining traction, providing patients with tools to manage their conditions more effectively. As technology continues to evolve, it is expected to enhance treatment accessibility and patient engagement, thereby driving growth in the neuropsychiatric disorders-treatment market. ## Future Outlook The [Neuropsychiatric Disorders Treatment Market](https://www.marketresearchfuture.com/reports/neuropsychiatric-disorders-treatment-market-1281) is projected to grow at a 10.5% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of personalized medicine approaches in treatment protocols By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Disorders: Degenerative Diseases (Largest) vs. Neurotic Disorders (Fastest-Growing) In the UK neuropsychiatric disorders-treatment market, the distribution of market share among various disorders reveals that degenerative diseases constitute the largest segment. These diseases, including Alzheimer's and other forms of dementia, account for a significant portion of the market due to the aging population and increasing prevalence. Conversely, neurotic disorders such as anxiety and depression are witnessing rapid growth and gaining traction, driven by rising awareness and better diagnosis. The growth trends in this market segment show that while degenerative diseases continue to command substantial attention due to their chronic nature, neurotic disorders are emerging as the fastest-growing category. This growth is fueled by a combination of evolving treatment modalities and a shift in societal attitudes towards mental health, leading to more patients seeking help. Additionally, advancements in pharmaceutical developments and increased healthcare spending further bolster the prospects of neurotic disorder treatments in the market. Degenerative Diseases: Dominant vs. Neurotic Disorders: Emerging Degenerative diseases remain the dominant force within the UK neuropsychiatric disorders-treatment market, characterized by long-term chronic conditions that significantly impact elderly populations. These disorders generally require ongoing care and management, making them a focus for providers and policymakers. On the other hand, neurotic disorders, defined by conditions such as anxiety disorders, obsessive-compulsive disorder (OCD), and personality disorders, are emerging with increasing prevalence and shifting public perception. These disorders are often less stigmatized now, resulting in higher diagnosis rates, thereby enhancing their market potential. Continued research and development in effective treatment options for neurotic disorders are expected to sustain their rapid growth trajectory, while degenerative diseases maintain a stable, if not dominant, market presence. ### By Treatment: Drug Treatment (Largest) vs. Shock Treatment (Fastest-Growing) In the UK neuropsychiatric disorders-treatment market, the distribution of market share among various treatment modalities reveals that Drug Treatment holds the largest segment. This treatment approach is widely adopted due to its effectiveness and broad acceptance within clinical settings, representing a significant portion of the market. In contrast, Shock Treatment, while smaller in share, is rapidly gaining attention and increasing its presence, particularly for treatment-resistant cases. Growth trends indicate a strong upward trajectory for Shock Treatment as new research and improved techniques enhance its safety and efficacy. The increasing incidence of neuropsychiatric disorders among the population drives demand for diverse treatment options. Innovations in drug therapy continue to bolster Drug Treatment's dominance, showcasing its vital role in managing various conditions effectively. Drug Treatment: Dominant vs. Shock Treatment: Emerging Drug Treatment remains the dominant approach in the segment, characterized by a wide range of medications designed to address various neuropsychiatric disorders. It enjoys support from healthcare professionals for its proven efficacy and established protocols. On the other hand, Shock Treatment, though still emerging, is being re-evaluated in light of new studies that advocate for its benefits in specific cases. This therapy involves carefully controlled electrical stimulation of the brain and is gaining traction among those seeking alternative solutions when traditional methods fail. Both segments serve critical roles in addressing the spectrum of neuropsychiatric disorders, yet their characteristics and responses from the medical community vary significantly. ### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the UK neuropsychiatric disorders-treatment market, the distribution of market share among end users highlights hospitals as the largest contributors, mainly due to their comprehensive facilities and specialized staff. Clinics follow, gaining traction as they provide accessible and focused treatment options tailored for patients with neuropsychiatric disorders. Research centres and other entities play a smaller but significant role, with research centres increasingly collaborating with hospitals to enhance treatment protocols. Growth trends in this segment are driven by rising awareness of mental health issues and an increase in the number of treatment facilities. Hospitals continue to dominate due to their established infrastructure, while clinics are emerging as the fastest-growing segment, attributed to the shift towards more personalized and accessible care. Factors such as government initiatives to improve mental health services also contribute to this dynamic growth landscape. Hospitals: Dominant vs. Clinics: Emerging Hospitals are characterized by their comprehensive range of services, state-of-the-art facilities, and the ability to handle severe psychiatric cases. This dominance is further supported by the presence of multidisciplinary teams that manage complex treatments efficiently. In contrast, clinics, often seen as the emerging force, offer specialized, less formal settings for treatment. They focus on outpatient services, making mental health care more accessible to patients who may not require hospitalization. The emergence of clinics reflects a changing perspective towards mental health treatment, prioritizing convenience and patient-centric care, which aligns with societal shifts towards destigmatizing mental health issues. ## Competitive Benchmarking The neuropsychiatric disorders-treatment market in the UK is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Key players such as Johnson & Johnson (US), Pfizer (US), and Eli Lilly and Company (US) are actively shaping the market through strategic initiatives focused on research and development, partnerships, and digital transformation. These companies are not only investing in novel drug formulations but are also exploring collaborations with technology firms to enhance treatment delivery and patient engagement, thereby fostering a more integrated approach to mental health care.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they leverage their resources and expertise to establish a strong foothold in the neuropsychiatric treatment sector. In October Johnson & Johnson (US) announced a strategic partnership with a leading AI firm to develop predictive analytics tools aimed at improving patient outcomes in neuropsychiatric treatments. This move is likely to enhance their product offerings by integrating advanced technology into treatment protocols, potentially setting a new standard for personalized care in the sector. In September Pfizer (US) launched a new digital platform designed to facilitate remote monitoring of patients undergoing treatment for depression and anxiety. This initiative not only reflects a commitment to patient-centric care but also positions Pfizer as a leader in the digital transformation of mental health services, which could significantly improve adherence and treatment efficacy. In August Eli Lilly and Company (US) expanded its research capabilities by establishing a new facility in the UK dedicated to neuropsychiatric drug development. This strategic investment underscores the company's focus on innovation and its intent to accelerate the development of next-generation therapies, which may enhance its competitive edge in a rapidly evolving market. As of November current trends in the neuropsychiatric disorders-treatment market indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence into treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will likely evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, thereby enhancing overall patient care and outcomes. ## Recent News & Developments The UK Neuropsychiatric Disorders Treatment Market is experiencing significant developments, particularly highlighted by increased investments in mental health therapies. AstraZeneca and Johnson & Johnson are advancing their portfolios, focusing on innovative drugs to tackle neuropsychiatric conditions. In recent months, collaborations involving Roche and Merck have aimed at enhancing the development of therapy, targeting conditions like depression and schizophrenia. Notably, in June 2023, Pfizer announced an expansion in its neuropsychiatry research division, indicating a commitment to addressing urgent treatment gaps in the UK. Mergers and acquisitions have also been notable, with AkzoNobel acquiring a biotech firm in August 2023, strengthening their position in the neuropsychiatric field. Furthermore, the UK government has been investing in mental health initiatives, seeking to allocate 2.3 billion towards mental health support by 2024, reflecting a growing acknowledgment of neuropsychiatric disorders' impact on public health. The market has seen overall growth, with the valuation reaching approximately 1.5 billion in late 2022, significantly influencing treatment accessibility and innovation across the sector. As companies like Novartis and Eli Lilly press on with research funding, the UK market anticipates further advancements in therapeutic solutions. ## Report Scope | MARKET SIZE 2024 | 5.45(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 6.02(USD Billion) | | MARKET SIZE 2035 | 16.35(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.5% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Johnson & Johnson (US), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Roche (CH), Otsuka Pharmaceutical (JP) | | Segments Covered | Disorders, Treatment, End User | | Key Market Opportunities | Integration of digital therapeutics and personalized medicine in neuropsychiatric disorders-treatment market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition in the neuropsychiatric disorders-treatment market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation of the UK neuropsychiatric disorders-treatment market in 2024?** A: The market valuation was 5.45 USD Billion in 2024. **Q: What is the projected market valuation for the UK neuropsychiatric disorders-treatment market by 2035?** A: The projected valuation for 2035 is 16.35 USD Billion. **Q: What is the expected CAGR for the UK neuropsychiatric disorders-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 10.5%. **Q: Which segments contributed to the UK neuropsychiatric disorders-treatment market in 2024?** A: Key segments included Degenerative Diseases at 0.9 USD Billion, Neurotic Disorders at 1.5 USD Billion, and Psychosis at 1.2 USD Billion. **Q: What are the projected values for the Drug Treatment segment by 2035?** A: The Drug Treatment segment is projected to reach 10.5 USD Billion by 2035. **Q: Which key players are leading the UK neuropsychiatric disorders-treatment market?** A: Key players include Johnson & Johnson, Pfizer, Eli Lilly and Company, and AstraZeneca. **Q: What is the expected growth for the Hospitals segment in the UK neuropsychiatric disorders-treatment market?** A: The Hospitals segment is projected to grow from 1.63 USD Billion in 2024 to 4.92 USD Billion by 2035. **Q: How does the performance of the Neurotic Disorders segment compare to others in 2024?** A: The Neurotic Disorders segment had a valuation of 1.5 USD Billion, indicating strong performance relative to other segments. **Q: What is the projected value for the Others segment in the Treatment category by 2035?** A: The Others segment in the Treatment category is projected to reach 4.35 USD Billion by 2035. **Q: What is the significance of research centres in the UK neuropsychiatric disorders-treatment market?** A: Research Centres are expected to grow from 1.09 USD Billion in 2024 to 3.27 USD Billion by 2035, highlighting their importance. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-neuropsychiatric-disorders-treatment-market-45191*